CA2617506C - Immunogenic constructs useful for treating mycobacterium avium subspecies paratuberculosis (map) infection - Google Patents

Immunogenic constructs useful for treating mycobacterium avium subspecies paratuberculosis (map) infection Download PDF

Info

Publication number
CA2617506C
CA2617506C CA2617506A CA2617506A CA2617506C CA 2617506 C CA2617506 C CA 2617506C CA 2617506 A CA2617506 A CA 2617506A CA 2617506 A CA2617506 A CA 2617506A CA 2617506 C CA2617506 C CA 2617506C
Authority
CA
Canada
Prior art keywords
seq
amino acids
polypeptide
polynucleotide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2617506A
Other languages
English (en)
French (fr)
Other versions
CA2617506A1 (en
Inventor
John Hermon-Taylor
Timothy John Bull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HAV Vaccines Ltd
Original Assignee
HAV Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HAV Vaccines Ltd filed Critical HAV Vaccines Ltd
Publication of CA2617506A1 publication Critical patent/CA2617506A1/en
Application granted granted Critical
Publication of CA2617506C publication Critical patent/CA2617506C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2617506A 2005-08-09 2006-08-03 Immunogenic constructs useful for treating mycobacterium avium subspecies paratuberculosis (map) infection Active CA2617506C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70659405P 2005-08-09 2005-08-09
US60/706,594 2005-08-09
PCT/GB2006/002893 WO2007017635A1 (en) 2005-08-09 2006-08-03 Immunogenic constructs

Publications (2)

Publication Number Publication Date
CA2617506A1 CA2617506A1 (en) 2007-02-15
CA2617506C true CA2617506C (en) 2015-02-03

Family

ID=36992793

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2617506A Active CA2617506C (en) 2005-08-09 2006-08-03 Immunogenic constructs useful for treating mycobacterium avium subspecies paratuberculosis (map) infection

Country Status (11)

Country Link
US (2) US7892566B2 (https=)
EP (1) EP1913020B1 (https=)
JP (1) JP5244593B2 (https=)
AT (1) ATE466876T1 (https=)
AU (1) AU2006277828B2 (https=)
CA (1) CA2617506C (https=)
DE (1) DE602006014164D1 (https=)
DK (1) DK1913020T3 (https=)
ES (1) ES2345274T3 (https=)
NZ (1) NZ565695A (https=)
WO (1) WO2007017635A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806093D0 (en) 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
ATE466876T1 (de) * 2005-08-09 2010-05-15 Hav Vaccines Ltd Immunogene konstrukte
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
CN109125740B (zh) * 2017-06-28 2022-04-05 成都威斯克生物医药有限公司 一种新型的肿瘤疫苗及其用途
GB201811382D0 (en) * 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
WO2026041756A1 (en) * 2024-08-21 2026-02-26 Hav Vaccines Limited Treatment of crohn's disease by mycobacterium avium subsp. paratuberculosis agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225324A (en) * 1987-04-24 1993-07-06 Bioscience International, Inc. Diagnostics for mycobacteria in public health, medical, and veterinary practice
GB8709803D0 (en) 1987-04-24 1987-05-28 Mcfadden J J Treatment of crohn's disease &c
FR2682967B1 (fr) 1991-10-25 1994-01-14 Pasteur Institut Nouveau promoteur de m. paratuberculosis. son utilisation pour le clonage et l'expression de sequences nucleotidiques.
AU708456B2 (en) * 1994-12-20 1999-08-05 New Zealand Pastoral Agriculture Research Institute Limited Methods and compositions for detecting and treating mycobacterial infections using an ahpCF operon
GB9526178D0 (en) 1995-12-21 1996-02-21 Taylor John Hermon Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
GB9806093D0 (en) 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
EP2196473A1 (en) * 2001-07-04 2010-06-16 Health Protection Agency Mycobacterial antigens expressed during latency
WO2003009868A1 (en) * 2001-07-26 2003-02-06 Otago Innovation Limited Antigenic compositions
JP2005514041A (ja) * 2002-01-11 2005-05-19 イーデー−レリースタツト・インステイテユート・フオール・デイールホウデライ・エイ・デイールゲゾントハイト・ベー・ベー ミコバクテリウム・パラツベルクローシス感染の診断薬及びワクチン
ATE466876T1 (de) * 2005-08-09 2010-05-15 Hav Vaccines Ltd Immunogene konstrukte

Also Published As

Publication number Publication date
WO2007017635A1 (en) 2007-02-15
AU2006277828A1 (en) 2007-02-15
EP1913020B1 (en) 2010-05-05
EP1913020A1 (en) 2008-04-23
NZ565695A (en) 2011-01-28
ES2345274T3 (es) 2010-09-20
US8147850B2 (en) 2012-04-03
US7892566B2 (en) 2011-02-22
JP5244593B2 (ja) 2013-07-24
DK1913020T3 (da) 2010-08-09
DE602006014164D1 (de) 2010-06-17
US20110129502A1 (en) 2011-06-02
AU2006277828B2 (en) 2012-02-02
CA2617506A1 (en) 2007-02-15
JP2009504149A (ja) 2009-02-05
ATE466876T1 (de) 2010-05-15
US20090203593A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
US11759516B2 (en) Nucleic acid vaccine against the SARS-CoV-2 coronavirus
CN102666575B (zh) 分枝杆菌疫苗
CN115246874B (zh) 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
US20210283242A1 (en) Immune-mediated coronavirus treatments
US8147850B2 (en) Immunogenic constructs
US20250152691A1 (en) Immunogenic composition for paratuberculosis
KR101955365B1 (ko) 신규한 클로스트리듐 디피실(Clostridium Difficile) DNA 백신
US20120003241A1 (en) Vaccine against botulism
WO1997013858A2 (en) Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
AU2011201813A1 (en) Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer
WO2023013787A1 (ja) Ｓｎａｒｅを活用した核酸構築物
US20130273093A1 (en) Method for Immunising a Subject against Mycobacterium Tuberculosis or Mycobacterium Bovis

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250617

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250617